Alseres Pharmaceuticals, Inc.
ALSE · OTC
6/30/2014 | 3/31/2014 | 12/31/2013 | 9/30/2013 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | -95.6% | 2,170.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 95% | 95% | 94.3% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -1,720.5% | -1,793.9% | 24% | -1,605.9% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -1,741.5% | -1,801.3% | 57.1% | -1,969.4% |
| EPS | -52.39 | -54.19 | 50 | -50 |
| % Growth | 3.3% | -208.4% | 200% | – |
| EPS Diluted | -52.39 | -54.19 | 50 | -50 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -1,720.5% | -1,793.9% | 85.1% | -1,605.9% |